Advertisement

Topics

J&J completes Actelion acquisition for $30bn

19:00 EDT 18 Jun 2017 | Pharmaceutical Technology

Johnson & Johnson (J&J) has completed the acquisition of Actelion Pharmaceuticals for approximately $30bn in an all-cash transaction through its Swiss subsidiary Janssen Holding.

Original Article: J&J completes Actelion acquisition for $30bn

NEXT ARTICLE

More From BioPortfolio on "J&J completes Actelion acquisition for $30bn"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...